Compare BigBearai Holdings Inc (BBAI) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BigBearai Holdings Inc vs Regeneron Pharmaceuticals Inc — how do they compare? BigBearai Holdings Inc trades at $3.12 (market cap $1.48B), while Regeneron Pharmaceuticals Inc trades at $655.5 (market cap $69.52B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 47× BigBearai Holdings Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.57% dividend while BigBearai Holdings Inc pays none. Which is the better fit depends on your goals.
| BBAI | REGN | |
|---|---|---|
Market Cap | $1.48B | $69.52B |
Sector | Technology | Health |
52-Week High | $8.91 | $812.27 |
52-Week Low | $3.05 | $542.52 |
Enterprise Value | $1.15B | $63.47B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BigBear.ai (BBAI) trades at $3.08, down 5.81% over 24 hours amid ongoing profitability challenges. The stock shows a bearish technical trend with mixed oscillators, while fundamentals reveal significant losses with a net income margin of -226.69% in 2025. Recent news highlights contract wins in airport security but notes persistent cash burn and flat revenue growth.
Outlook remains cautious due to deep losses and high valuation multiples, though backlog growth and debt reduction offer potential upside. Key risks include sustained negative cash flow and competitive pressures in the AI sector. Analyst consensus is predominantly Hold, reflecting uncertainty over near-term profitability improvements.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BigBearai Holdings Inc
BigBearai Holdings Inc is a specialized provider of AI-driven decision intelligence solutions, primarily serving the U.S. defense, intelligence, and national security communities. It operationalizes complex data into actionable insights through its core modules—Observe, Orient, and Dominate—to support mission-critical operations and logistics.
Read more on BBAI →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
